Bruker Co. (NASDAQ:BRKR) Expected to Announce Earnings of $0.38 Per Share
Analysts forecast that Bruker Co. (NASDAQ:BRKR) will announce $0.38 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Bruker’s earnings, with estimates ranging from $0.37 to $0.39. Bruker reported earnings of $0.37 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 2.7%. The firm is scheduled to announce its next earnings results on Thursday, November 7th.
On average, analysts expect that Bruker will report full year earnings of $1.61 per share for the current year, with EPS estimates ranging from $1.58 to $1.63. For the next fiscal year, analysts anticipate that the company will report earnings of $1.84 per share, with EPS estimates ranging from $1.79 to $1.88. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Bruker.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 1st. The medical research company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. Bruker had a net margin of 9.57% and a return on equity of 27.10%. The firm had revenue of $490.20 million during the quarter, compared to the consensus estimate of $477.70 million. During the same period in the prior year, the firm earned $0.25 EPS. The business’s revenue was up 10.5% on a year-over-year basis.
Bruker stock traded up $0.30 during mid-day trading on Friday, reaching $43.94. The company had a trading volume of 209,341 shares, compared to its average volume of 543,559. The company has a quick ratio of 1.27, a current ratio of 2.19 and a debt-to-equity ratio of 0.63. Bruker has a 52 week low of $26.10 and a 52 week high of $51.41. The company has a 50 day moving average of $43.42 and a 200-day moving average of $43.52. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 31.39, a PEG ratio of 2.18 and a beta of 1.39.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Tuesday, September 3rd were paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.36%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio is 11.43%.
In related news, VP Mark Munch sold 47,203 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $42.87, for a total transaction of $2,023,592.61. Following the completion of the sale, the vice president now owns 96,063 shares in the company, valued at approximately $4,118,220.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Burkhard Prause sold 15,702 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $42.96, for a total transaction of $674,557.92. Following the sale, the chief executive officer now owns 1,338 shares of the company’s stock, valued at approximately $57,480.48. The disclosure for this sale can be found here. Corporate insiders own 26.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in shares of Bruker by 0.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,691,185 shares of the medical research company’s stock worth $1,483,075,000 after purchasing an additional 180,171 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Bruker by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 10,866,673 shares of the medical research company’s stock worth $542,789,000 after purchasing an additional 156,591 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Bruker by 1.1% during the 2nd quarter. Janus Henderson Group PLC now owns 3,335,079 shares of the medical research company’s stock worth $166,587,000 after purchasing an additional 36,643 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Bruker by 1.2% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 1,924,095 shares of the medical research company’s stock worth $96,109,000 after purchasing an additional 22,812 shares in the last quarter. Finally, Invesco Ltd. increased its position in Bruker by 2,436.8% in the 2nd quarter. Invesco Ltd. now owns 1,698,456 shares of the medical research company’s stock valued at $84,838,000 after acquiring an additional 1,631,502 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.